Carmustine

Product manufactured by Sti Pharma Llc

Application Nr Approved Date Route Status External Links
ANDA209278 None None None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

1 Indications And Usage Carmustine For Injection Is A Nitrosourea Indicated As Palliative Therapy As A Single Agent Or In Established Combination Therapy With Other Approved Chemotherapeutic Agents In The Following: Brain Tumors Glioblastoma, Brainstem Glioma, Medulloblastoma, Astrocytoma, Ependymoma, And Metastatic Brain Tumors (1) Multiple Myeloma-In Combination With Prednisone (1) Relapsed Or Refractory Hodgkin's Lymphoma In Combination With Other Approved Drugs (1) Relapsed Or Refractory Non-Hodgkin's Lymphomas In Combination With Other Approved Drugs (1) Carmustine For Injection Is Indicated As Palliative Therapy As A Single Agent Or In Established Combination Therapy In The Following: Brain Tumors Glioblastoma, Brainstem Glioma, Medulloblastoma, Astrocytoma, Ependymoma, And Metastatic Brain Tumors. Multiple Myeloma In Combination With Prednisone. Relapsed Or Refractory Hodgkin's Lymphoma In Combination With Other Approved Drugs. Relapsed Or Refractory Non-Hodgkin's Lymphomas In Combination With Other Approved Drugs.

All Formulated Excipients (0 Total)

None

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Carmustine CARMUSTINE ZINC3830387

Comments